EORTC – The first patient has been enrolled in the STREXIT 2 study
EORTC shared a post by
“We are excited to announce that the first patient has been enrolled in the EU-funded STREXIT 2 study!
STREXIT 2 is an extension of the ongoing EORTC STRASS 2 phase III clinical trial, which investigates the benefits of giving chemotherapy before surgery to patients with high-risk retroperitoneal sarcoma.
STREXIT 2 will add an observational arm to include real-world data from patients who are not part of the STRASS 2 trial. This aims to compare outcomes between patients in the STRASS 2 trial and those in the STREXIT 2 observational group, thereby strengthening the trial results.”
Quoting ‘s post:
“Learn more about clinical studies in cancer research, the role of real-world evidence in Strexit 2, and the purpose of the international collaboration in this multi-national European project.
STREXIT 2 is funded by the European Union and is under the legal sponsorship of EORTC – European Organisation for Research and Treatment of Cancer.”
Source: EORTC/LinkedIn and /LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023